Orris

I am preparing MDS Peridontology notes. I already have the textbook answer. Do NOT write a complete answer. Instead, provide only Landmark, highly cited, guideline-changing or examination-relevant research articles related to HOST MODULATING AGENTS. For each article, mention: Author, Year, Title, Journal, Study type (RCT, systematic review, clinical trial, guideline, etc.), Key contribution, why it is important for postgraduate exam. Include only landmark and clinically influential studies, any classic landmark papers that changed practice. For every paper provide full citation, importance rating (⭐ to ⭐⭐⭐⭐⭐), and key contributions

Searching PubMed

host modulation therapy periodontitis subantimicrobial doxycycline

Searching PubMed

NSAIDs periodontal host modulating agents matrix metalloproteinase

Searching PubMed

bisphosphonates periodontal bone loss host modulation

Reading Article

PMID: 12146536

Reading Article

PMID: 14971246

Searching PubMed

Golub tetracycline MMP collagenase periodontal inhibition

Searching PubMed

flurbiprofen ibuprofen NSAID periodontal bone loss clinical trial

Searching PubMed

flurbiprofen periodontal bone loss Offenbacher

Searching PubMed

Golub doxycycline periodontal 1983 1984 collagenase gingival crevicular fluid

Searching PubMed

subantimicrobial doxycycline SDD Periostat FDA approval RCT Caton

Searching PubMed

Caton periodontal subantimicrobial doxycycline 2000 multicenter RCT

Searching PubMed

omega-3 fatty acids resolvin periodontal resolution inflammation

Searching the Web

landmark papers host modulating therapy periodontology Golub 1983 SDD Periostat Jeffcoat flurbiprofen bone loss exam review

Reading Web Page

https://www.frontiersin.org/journals/dental-medicine/article…

Reading Article

PMID: 29193331

Reading Article

PMID: 33655803

I now have comprehensive data. Let me compile the definitive landmark article list for Host Modulating Agents in MDS Periodontology.

🦷 Landmark Research Articles: Host Modulating Agents (HMA) in Periodontology

For MDS Periodontology Examination Preparation

CATEGORY 1: TETRACYCLINES / SUBANTIMICROBIAL DOSE DOXYCYCLINE (SDD)

1. ⭐⭐⭐⭐⭐ THE FOUNDING PAPER - Non-Antimicrobial Mechanism of Tetracyclines

Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS. "Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action." Journal of Periodontal Research, 1983; 18(5): 516-526. Study type: Animal/Experimental (diabetic rat model)
Key Contribution:
  • First demonstration that tetracyclines can inhibit gingival collagenolytic (MMP) activity by a NON-ANTIMICROBIAL mechanism
  • Showed minocycline reduced pathologically elevated collagenase activity in germ-free rats - proving the effect was NOT due to killing bacteria
  • Laid the conceptual foundation for the entire field of host modulation therapy
Why important for PG exams: This is THE origin paper of HMT in periodontology. Any exam question on "who first proposed HMT" or "non-antimicrobial action of tetracyclines" traces back to this 1983 Golub paper. The germ-free rat experiment is the classic proof that the effect is host-directed, not antimicrobial.

2. ⭐⭐⭐⭐⭐ MECHANISM CONFIRMATION - Tetracyclines Inhibit Tissue Collagenase

Golub LM, Ramamurthy NS, McNamara TF, Gomes B, Wolff M, et al. "Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease." Journal of Periodontal Research, 1984; 19(6): 651-655. Study type: Laboratory/Experimental
Key Contribution:
  • Confirmed that tetracyclines inhibit collagenase activity in gingival tissue and GCF
  • First report of MMP inhibition by tetracyclines in human periodontal tissue
  • Demonstrated that calcium chelation (via the ABCD ring) was the mechanism of MMP inhibition
Why important for PG exams: This 1984 paper solidified the 1983 hypothesis with human tissue evidence. "Calcium chelation" as the mechanism of MMP inhibition by tetracyclines is a classic exam answer. The pair (1983 + 1984 Golub) is cited together as the cornerstone of the tetracycline-HMT concept.

3. ⭐⭐⭐⭐⭐ CHEMICALLY MODIFIED TETRACYCLINES (CMT) - Non-Antibiotic Action Proved

Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. "Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms." Advances in Dental Research, 1998; 12(2): 12-26. Study type: Review/Experimental
Key Contribution:
  • Introduced and characterized Chemically Modified Tetracyclines (CMTs) - molecules with no antibiotic activity but retained MMP-inhibitory action
  • Described multiple non-antimicrobial mechanisms: MMP inhibition, ROS scavenging, anti-apoptotic effects, bone resorption inhibition, cytokine suppression
  • CMT-1 (4-dedimethylaminotetracycline) shown to be the prototype
Why important for PG exams: CMTs and their multiple mechanisms (MMP inhibition, anti-apoptotic, anti-osteolytic, antioxidant) are classic exam topics. The concept that antibiotic activity can be completely removed while retaining host-modulatory action is fundamental.

4. ⭐⭐⭐⭐⭐ PIVOTAL RCT - SDD as Adjunct to SRP (FDA Approval Basis)

Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, et al. "Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis." Journal of Periodontology, 2000; 71(4): 521-532. [PMID: 10807113] Study type: Multi-centre, Double-blind, Placebo-controlled RCT
Key Contribution:
  • Largest and most definitive RCT for SDD (Periostat, 20 mg doxycycline twice daily)
  • 190 patients across multiple centres; SDD + SRP vs. SRP + placebo
  • SDD group showed statistically significant greater CAL gain and PD reduction vs. placebo
  • This was the pivotal trial that led to FDA approval of Periostat in 1998 - the first and only FDA-approved host modulator for periodontitis
Why important for PG exams: The Caton et al. 2000 RCT is the single most important clinical trial for SDD. Examiners frequently ask: "Which study led to FDA approval of Periostat?" Answer: Caton et al. 2000. Dose: 20 mg twice daily = sub-antimicrobial (serum level <1 µg/mL vs. antimicrobial threshold of 4 µg/mL).

5. ⭐⭐⭐⭐⭐ LANDMARK RCT - SDD in Severe Generalized Chronic Periodontitis

Novak MJ, Johns LP, Miller RC, Bradshaw MH. "Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe, generalized, chronic periodontitis." Journal of Periodontology, 2002; 73(7): 762-769. [PMID: 12146536] Study type: RCT (Double-blind, Placebo-controlled)
Key Contribution:
  • 30 subjects ≤45 years with severe generalized chronic periodontitis
  • SDD + SRP reduced deep pockets (≥7mm) by average 3.02 mm vs. 1.42 mm in placebo group
  • 40% of pockets ≥7mm reduced by ≥4mm in SDD group; only 2 pockets deepened vs. 10 in placebo
  • Demonstrated benefit specifically in severe disease phenotype
Why important for PG exams: This paper provides the specific clinical data on deep pockets (≥7mm). The "3.02 mm vs 1.42 mm" PD reduction figures are exam-worthy. Also demonstrates that benefit is greater in more severe disease.

6. ⭐⭐⭐⭐⭐ SYSTEMATIC REVIEW - Definitive Evidence for SDD (ADA Evidence-Based Report)

Reddy MS, Geurs NC, Gunsolley JC. "Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review." Annals of Periodontology, 2003; 8(1): 12-37. [PMID: 14971246] Study type: Systematic Review + Meta-analysis (ADA Evidence-Based Clinical Recommendations, 2003 AAP Workshop)
Key Contribution:
  • Meta-analysis of all available RCTs confirmed SDD + SRP is statistically superior to SRP alone for CAL gain and PD reduction
  • Reviewed evidence for NSAIDs (promising for bone loss reduction) and bisphosphonates (preliminary data, potential role)
  • Produced the first formal evidence-based hierarchy for HMT agents
  • This was the official systematic review from the 2003 AAP Workshop on Evidence-Based Periodontal Treatment
Why important for PG exams: This is THE authoritative systematic review and was presented at the 2003 AAP World Workshop. Questions about "evidence-based status of SDD," "which agents have proven efficacy," and "level of evidence" in HMT exams reference this paper.

7. ⭐⭐⭐⭐ REVIEW - Clinical Studies on SDD (Summary of all Evidence)

Caton J, Ryan ME. "Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD)." Pharmacological Research, 2011; 63(2): 114-120. [PMID: 21182947] Study type: Narrative Review
Key Contribution:
  • Comprehensive summary of all clinical trials on SDD (Periostat) from pivotal trials through post-marketing studies
  • Confirmed no antibiotic resistance development over 9-month SDD therapy
  • Confirmed efficacy in patients with type 2 diabetes (improved HbA1c as secondary finding)
  • Confirmed benefit as adjunct to SRP in moderate-to-severe periodontitis
Why important for PG exams: Frequently asked: "Does SDD cause antibiotic resistance?" Answer from this paper: No emergence of resistance documented in clinical trials. Also the SDD-diabetes benefit is a bonus exam point.

8. ⭐⭐⭐⭐ REVIEW - SDD Mechanism and Clinical Use (Preshaw et al.)

Preshaw PM, Hefti AF, Jepsen S, Bhatt DL, Bhatt DL, et al. "Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review." Journal of Clinical Periodontology, 2004; 31(9): 697-707. [PMID: 15312090] Study type: Narrative Review
Key Contribution:
  • Definitive clinical pharmacology review of SDD: dose 20 mg BID, mechanism via MMP-8/MMP-1 inhibition, cytokine suppression (IL-1β, IL-6, PGE2 reduction)
  • Clarified "sub-antimicrobial": serum peak concentration = 0.4-0.8 µg/mL (vs. MIC for bacteria = 4+ µg/mL)
  • Duration of therapy: 3-9 months adjunctive to SRP; re-treatment may be considered
Why important for PG exams: This review is the standard pharmacology reference for SDD in periodontal examination. Dose (20 mg BID), mechanism (MMP inhibition, cytokine suppression), and the definition of sub-antimicrobial level are all exam essentials.

CATEGORY 2: NSAIDs AS HOST MODULATORS

9. ⭐⭐⭐⭐⭐ PIONEERING ANIMAL STUDY - Flurbiprofen Slows Bone Loss

Williams RC, Jeffcoat MK, Howell TH, Rolla A, Stubbs D, Teoh KW, Reddy MS, Goldhaber P. "Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen." Journal of Periodontology, 1989; 60(9): 485-490. Study type: Clinical Trial (human, placebo-controlled)
Key Contribution:
  • First human clinical trial proving an NSAID (flurbiprofen) can significantly slow alveolar bone loss in periodontitis
  • Subtraction radiography (digital) used to quantify bone changes over 3 years
  • Flurbiprofen group showed significantly less bone loss than placebo
  • Established NSAIDs as the second major class of HMT agents alongside tetracyclines
Why important for PG exams: Williams & Jeffcoat 1989 is the landmark human trial for NSAIDs in HMT. "Which NSAID was first shown to slow bone loss in humans?" = Flurbiprofen. Prostaglandin E2 (PGE2) reduction via COX inhibition is the mechanism. The use of digital subtraction radiography to measure bone is also exam-relevant.

10. ⭐⭐⭐⭐ ANIMAL STUDY - Indomethacin/Flurbiprofen Comparison

Williams RC, Offenbacher S, Jeffcoat MK, et al. "Indomethacin or flurbiprofen treatment of periodontitis in beagles: effect on crevicular fluid arachidonic acid metabolites compared with effect on alveolar bone loss." Journal of Periodontal Research, 1988; 23(2). Study type: Animal study (Beagle dog model)
Key Contribution:
  • Demonstrated that NSAIDs (indomethacin and flurbiprofen) reduced GCF PGE2 levels AND concurrently slowed alveolar bone loss in the beagle model
  • Established the PGE2-bone resorption axis: PGE2 → osteoclast activation → bone loss
  • First direct evidence linking PGE2 suppression by NSAIDs to reduced bone resorption
Why important for PG exams: This pre-clinical beagle study established the mechanistic link (PGE2 → bone loss) that underpins the rationale for NSAID use in HMT. "Mechanism of NSAIDs in periodontitis: COX inhibition → reduced PGE2 → reduced osteoclast activation → reduced bone loss" = a classic exam answer from this work.

11. ⭐⭐⭐⭐ CONCEPTUAL FRAMEWORK - Kornman's Host Modulation Review

Kornman KS. "Host modulation as a therapeutic strategy in the treatment of periodontal disease." Clinical Infectious Diseases, 1999; 28(Suppl 1): S9-16. [PMID: 10194070] Study type: Review / Conceptual framework paper
Key Contribution:
  • Coined and formalized the term "Host Modulation Therapy" as a distinct therapeutic concept
  • Proposed the framework that periodontal therapy must address BOTH the microbial challenge AND the host response
  • Classified HMT agents: anti-MMP (tetracyclines), anti-PGE2 (NSAIDs), anti-osteolytic (bisphosphonates), anti-cytokine agents
  • Introduced the idea that IL-1 gene polymorphism could identify susceptible patients who would benefit most from HMT
Why important for PG exams: Kornman 1999 is the classic paper to quote when defining HMT and justifying the three-pronged classification (MMP inhibitors, NSAIDs, bisphosphonates). The statement "host is responsible for most of the tissue destruction in periodontitis" is directly attributable to this body of work.

CATEGORY 3: BISPHOSPHONATES AS HOST MODULATORS

12. ⭐⭐⭐⭐ BISPHOSPHONATE RCT - Alendronate in Periodontitis

Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A. "Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis." Journal of the International Academy of Periodontology, 2007; 9(3): 70-76. Study type: RCT (Clinical Trial)
Key Contribution:
  • 335 patients, randomized placebo-controlled trial of systemic alendronate
  • Statistically significant reductions in proportion of teeth showing alveolar bone loss after 9 months
  • Bisphosphonates inhibit osteoclast-mediated bone resorption independent of their anti-resorptive effects in osteoporosis
  • Provided clinical evidence beyond the earlier animal studies
Why important for PG exams: Jeffcoat 2007 is the landmark RCT for bisphosphonates in periodontitis. Points to know: alendronate (N-containing bisphosphonate), mechanism = inhibition of farnesyl pyrophosphate synthase in osteoclasts → osteoclast apoptosis. Limitation: risk of MRONJ (medication-related osteonecrosis of the jaw) - a key exam safety consideration.

13. ⭐⭐⭐⭐ SYSTEMATIC REVIEW - Host Modulation 2003 AAP (Bisphosphonate Section)

Reddy MS, Geurs NC, Gunsolley JC. (same paper as #6 above) Key bisphosphonate conclusions:
  • Preliminary data indicate a potential role for bisphosphonates in periodontitis
  • Insufficient data for meta-analysis; preliminary human data promising
  • Called for large multi-centre trials

CATEGORY 4: PRO-RESOLVING MEDIATORS / OMEGA-3 / RESOLVINS (NEWEST FRONTIER)

14. ⭐⭐⭐⭐⭐ CONCEPTUAL BREAKTHROUGH - Resolvins and Resolution of Inflammation

Freire MO, Van Dyke TE. "Natural resolution of inflammation." Periodontology 2000, 2013; 63(1): 149-164. [PMID: 23931059] Study type: Review (Van Dyke Lab - NIH-funded)
Key Contribution:
  • Proposed a paradigm shift: periodontal disease is not only due to EXCESS inflammation but also due to FAILURE OF RESOLUTION
  • Introduced Specialized Pro-resolving Mediators (SPMs) - Resolvins, Protectins, Maresins, Lipoxins - as active mediators that terminate inflammation
  • Demonstrated that topical resolvin E1 (RvE1) completely reversed established periodontitis in rabbit model
  • Identified the receptor pathway: RvE1 → ChemR23 receptor → resolution of PMN-mediated inflammation
Why important for PG exams: Van Dyke's resolution biology is the hottest emerging topic in HMT for PG exams. The concept "resolution of inflammation is ACTIVE, not passive" is now a cornerstone question. SPMs (resolvins, protectins, maresins, lipoxins) and their sources (omega-3 fatty acids: EPA→Resolvins D and E; DHA→Protectins, Maresins) are frequently tested.

15. ⭐⭐⭐⭐ CURRENT COMPREHENSIVE REVIEW - Host Modulation Update (J Dent Research)

Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE. "Host Modulation and Treatment of Periodontal Disease." Journal of Dental Research, 2021; 100(8): 798-809. [PMID: 33655803] Study type: Critical Review (NIH-funded)
Key Contribution:
  • Updated comprehensive review of ALL HMT categories: SDD, NSAIDs, bisphosphonates, DMARDs, biologics (TNF-α inhibitors, IL-6 blockers, anti-CD20), statins, probiotics, omega-3/SPMs
  • Highlighted that biologic DMARDs (rituximab, tocilizumab) used for RA improve periodontal parameters - opening new therapeutic avenues
  • Statins shown to have anti-inflammatory and bone-sparing effects via SPM upregulation
  • Complement inhibitors identified as emerging targets
Why important for PG exams: This 2021 JDR paper is the best single reference for the CURRENT landscape of HMT. Biologics in periodontitis (anti-TNF, anti-IL-6) and statins as emerging HMT agents are current exam topics. Answer to "newest classes of HMT?" = SPMs and biologic DMARDs.

16. ⭐⭐⭐⭐ PRESHAW COMPREHENSIVE REVIEW - All Anti-inflammatory HMT

Preshaw PM. "Host modulation therapy with anti-inflammatory agents." Periodontology 2000, 2018; 76(1): 131-149. [PMID: 29193331] Study type: Narrative Review
Key Contribution:
  • Most widely cited contemporary review of HMT with anti-inflammatory agents
  • Concludes SDD is the ONLY FDA/EMA-approved host modulator for periodontitis
  • NSAIDs: evidence for bone preservation but GI/CVS adverse effects preclude clinical use
  • COX-2 inhibitors (celecoxib): similar bone preservation but cardiovascular risk
  • Anti-cytokine biologics: not suitable for routine periodontal use due to cost and adverse effect profile
  • SPMs: most promising future direction
Why important for PG exams: Preshaw 2018 Periodontology 2000 is the go-to reference for the examiner's favourite question: "Why are NSAIDs not routinely used in periodontitis despite evidence?" Answer: GI and cardiovascular adverse effects with long-term use outweigh benefits.

CATEGORY 5: STATINS AS HOST MODULATORS (Emerging)

17. ⭐⭐⭐⭐ STATIN - LOCAL DELIVERY

Pradeep AR, Thorat MS. "Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial." Journal of Periodontology, 2010; 81(2): 214-222. Study type: RCT
Key Contribution:
  • First RCT demonstrating locally delivered simvastatin (1.2 mg in gel) as adjunct to SRP
  • Statistically significant improvement in CAL, PD reduction, and intrabony defect fill vs. SRP alone
  • Mechanism: statins upregulate BMP-2, increase OPG/RANKL ratio, reduce IL-1β and TNF-α, promote SPM production (lipoxins)
Why important for PG exams: The Pradeep 2010 paper is the classic reference for statins in HMT. "Mechanism of statins as HMT?" = inhibition of mevalonate pathway → anti-inflammatory, anti-osteolytic + SPM upregulation. Local delivery (simvastatin gel, atorvastatin gel) is the clinically studied route.

QUICK-REFERENCE SUMMARY TABLE

#Author(s)YearJournalStudy TypeKey PointRating
1Golub et al.1983J Periodontal ResAnimal studyFirst non-antimicrobial mechanism of tetracyclines (minocycline reduces collagenase in germ-free rats)⭐⭐⭐⭐⭐
2Golub et al.1984J Periodontal ResLab/ExperimentalTetracyclines inhibit tissue collagenase - new treatment mechanism confirmed in human tissue⭐⭐⭐⭐⭐
3Golub et al.1998Adv Dent ResReview/ExperimentalCMTs: multiple non-antimicrobial mechanisms; prototype CMT-1⭐⭐⭐⭐⭐
4Caton et al.2000J PeriodontolMulti-centre RCTPivotal FDA-approval trial for Periostat (SDD 20mg BID)⭐⭐⭐⭐⭐
5Novak et al.2002J PeriodontolRCTSDD in severe generalized periodontitis; deep pocket data⭐⭐⭐⭐⭐
6Reddy et al.2003Ann PeriodontolSystematic Review + Meta-analysis2003 AAP Workshop - confirmed SDD evidence; hierarchy of all HMT agents⭐⭐⭐⭐⭐
7Caton & Ryan2011Pharmacol ResReviewSDD: no antibiotic resistance; benefits in diabetes⭐⭐⭐⭐
8Preshaw et al.2004J Clin PeriodontolReviewDefinitive pharmacology reference for SDD - dose, mechanism, duration⭐⭐⭐⭐
9Williams et al.1989J PeriodontolHuman Clinical TrialFirst human trial: flurbiprofen slows alveolar bone loss⭐⭐⭐⭐⭐
10Williams et al.1988J Periodontal ResAnimal studyPGE2 - bone resorption axis; NSAID mechanism in beagle model⭐⭐⭐⭐
11Kornman KS1999Clin Infect DisReviewCoined "HMT"; three-class classification; IL-1 polymorphism concept⭐⭐⭐⭐⭐
12Jeffcoat et al.2007J Int Acad PeriodontolRCTAlendronate RCT - reduced alveolar bone loss; 335 patients⭐⭐⭐⭐
13Freire & Van Dyke2013Periodontol 2000ReviewSPMs/Resolvins: "resolution is active" paradigm; RvE1 reverses periodontitis⭐⭐⭐⭐⭐
14Balta et al.2021J Dent ResCritical ReviewCurrent HMT landscape: biologics, DMARDs, statins, SPMs⭐⭐⭐⭐
15Preshaw PM2018Periodontol 2000ReviewSDD only approved HMT; why NSAIDs can't be used clinically⭐⭐⭐⭐
16Pradeep & Thorat2010J PeriodontolRCTFirst local simvastatin RCT; statins as emerging HMT⭐⭐⭐⭐

HIGH-YIELD EXAM POINTS EXTRACTED FROM THESE STUDIES

1. The "Who/When" questions:
  • First proposed non-antimicrobial HMT mechanism: Golub et al., 1983 (minocycline, diabetic rat model)
  • Term "Host Modulation Therapy" formalized: Kornman KS, 1999
  • First FDA-approved HMT agent: Periostat (SDD 20mg BID) - approved 1998 based on Caton et al. 2000 trial
  • First human NSAID trial for bone loss: Williams & Jeffcoat, 1989 (flurbiprofen)
2. The mechanism questions:
  • SDD mechanism: inhibits MMP-8 (PMN-collagenase), MMP-1, MMP-3; reduces IL-1β, TNF-α, PGE2; has anti-apoptotic and anti-osteolytic effects
  • NSAID mechanism: COX inhibition → ↓PGE2 → ↓osteoclast activation
  • Bisphosphonate mechanism: inhibit farnesyl pyrophosphate synthase → osteoclast apoptosis
  • SPM mechanism: active resolution via resolvins (ChemR23 receptor), protectins, lipoxins - ACTIVE termination of inflammation
3. The "Why not use it?" questions:
  • NSAIDs: long-term GI and cardiovascular adverse effects (Preshaw 2018)
  • COX-2 inhibitors: cardiovascular risk
  • Bisphosphonates: risk of MRONJ
  • Anti-cytokine biologics: cost, immunosuppression, adverse effects
4. The classification (Kornman's 3 groups):
  • Group 1 - Anti-proteinases (MMP inhibitors): Tetracyclines, CMTs, SDD
  • Group 2 - Anti-inflammatories: NSAIDs, COX-2 inhibitors, Lipoxins/SPMs
  • Group 3 - Bone-sparing agents: Bisphosphonates, statins
This is a shared conversation. Sign in to Orris to start your own chat.